1. Home
  2. RCMT vs SPRO Comparison

RCMT vs SPRO Comparison

Compare RCMT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RCM Technologies Inc.

RCMT

RCM Technologies Inc.

HOLD

Current Price

$19.73

Market Cap

135.6M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.29

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCMT
SPRO
Founded
1971
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.6M
124.5M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
RCMT
SPRO
Price
$19.73
$2.29
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
40.8K
310.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.34
N/A
Revenue
$186,737,000.00
$47,977,000.00
Revenue This Year
$16.29
N/A
Revenue Next Year
$6.92
N/A
P/E Ratio
$14.89
N/A
Revenue Growth
5.83
N/A
52 Week Low
$13.20
$0.51
52 Week High
$28.19
$3.09

Technical Indicators

Market Signals
Indicator
RCMT
SPRO
Relative Strength Index (RSI) 54.87 47.97
Support Level $19.35 $2.15
Resistance Level $21.12 $2.44
Average True Range (ATR) 0.69 0.09
MACD 0.21 0.00
Stochastic Oscillator 67.19 53.00

Price Performance

Historical Comparison
RCMT
SPRO

About RCMT RCM Technologies Inc.

RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: